세계의 in situ 하이브리다이제이션 시장 예측(-2030년) : 오퍼링별, 기술별, 용도별, 최종사용자별, 지역별

The in situ hybridization market is expected to reach USD 2.35 billion in 2030 from USD 1.64 billion in 2025, at a CAGR of 7.4% during the forecast period. The expansion of the in situ hybridization (ISH) market is largely driven by continuous technological advancements within ISH platforms. Innovations such as enhanced probe designs, automation, and multiplexing capabilities have markedly improved assay sensitivity, specificity, and throughput. These enhancements align with the increasing need for precision medicine and the development of laboratory-developed tests (LDTs). Such advancements facilitate the identification of patient-specific genetic markers, solidifying ISH's role as a critical component in personalized treatment approaches. Furthermore, the emerging field of spatial transcriptomics within cancer and neuroscience research underscores the necessity for highly sensitive and multiplexed ISH technologies to analyze gene expression in its tissue context. This demand is propelling ongoing innovation in the ISH sector. Notably, ISH presents distinct advantages over immunohistochemistry (IHC), particularly with its ability to detect direct nucleic acid, which enhances diagnostic accuracy and disease characterization, further contributing to the market's growth.

"The fluorescent in situ hybridization technology segment accounted for the largest technology market share in 2024."

The in situ hybridization market by technology is segmented into fluorescent in situ hybridization and chromogenic in situ hybridization. The fluorescent in situ hybridization technology is further segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, and PNA fluorescent in situ hybridization. In 2024, the fluorescent in situ hybridization technology segment accounted for the largest market share, by technology. The dominant position of this technology segment is attributable to its exceptional sensitivity, specificity, and versatility in detecting genetic anomalies at both DNA and RNA levels. Fluorescence In Situ Hybridization (FISH) provides high-resolution insights for identifying chromosomal rearrangements, gene amplifications, and deletions, making it indispensable in cancer diagnostics, the identification of genetic disorders, and prenatal screenings. FISH enables concurrent detection of multiple targets through the use of various fluorescent probes, catering to both clinical and research needs. Furthermore, the extensive incorporation of FISH in personalized medicine, particularly for HER2 and ALK assessments in oncology, has significantly bolstered its demand in recent years.

"Consumables segment is projected to register the highest CAGR in the global in situ hybridization market during the forecast period."

By offering, the in situ hybridization market is segmented into consumables, instruments, services & software. The consumables segment is further sub-segmented into kits & reagents, probes & probe kits, and accessories & other consumables. The consumables segment is expected to register the highest growth rate during the forecast period. The expansion of the market for consumables in in situ hybridization (ISH) procedures is fundamentally linked to their increasing application in cancer diagnostics and various other disease areas. This uptick in utilization directly correlates with a heightened demand for essential consumables, including probes and probe kits, integral to every ISH assay. As testing volumes escalate in both clinical and research environments, the demand for these materials is poised for steady growth. Furthermore, the ongoing development and approval of advanced ISH-based diagnostic tests, such as Roche's VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, are anticipated to further broaden the consumables market. Such innovations enhance the accuracy and specificity of diagnostics for conditions such as B-cell malignancies, thereby incentivizing laboratories and healthcare facilities to increasingly incorporate ISH methodologies into their testing repertoire. This upward trajectory in clinical uptake will consistently drive the demand for corresponding consumables, underpinning robust growth in this segment. Additionally, it presents significant opportunities for key industry players to fortify their market presence through innovative product development and strategic supply chain enhancements.

"The Asia Pacific region is growing at the highest CAGR in the in situ hybridization market during the study period."

The Asia Pacific region is anticipated to experience the highest growth rate in the in situ hybridization (ISH) market throughout the forecast period. This growth is driven by significant advancements in healthcare infrastructure and heightened investments in molecular diagnostics and precision medicine from both government entities and private sector stakeholders. Key nations, including China, India, Japan, and South Korea, are actively advancing research initiatives in genomics and personalized medicine through targeted national programs and funding mechanisms. Concurrently, the increasing prevalence of chronic diseases-such as cancer, infectious diseases, and genetic disorders-is propelling the demand for sophisticated diagnostic technologies like ISH. The burgeoning presence of regional diagnostic firms, coupled with strategic partnerships with global entities, is further facilitating market access and enhancing technology adoption.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
• By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Bio-Techne. (US), and Biocare Medical (US) are some of the key players in the in situ hybridization market.

The study includes an in-depth competitive analysis of these key players in the in situ hybridization market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the in situ hybridization market by offering (consumables (kits & reagents, probes & probe kits, accessories & other consumables), instruments, services & software), technology (fluorescent in situ hybridization (DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization), chromogenic in situ hybridization), application (clinical diagnostics (cancer diagnostics, genetic disorder detection, infectious disease diagnostics, and others), research applications (neuroscience, immunology, others), drug discovery & development), end user (hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the in situ hybridization market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments, such as new product launches and acquisitions within the in situ hybridization market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall in situ hybridization market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers [technological advancements enhancing in situ hybridization capabilities, increasing adoption of in situ hybridization in precision medicine and laboratory-developed tests (LDTs), rising demand for spatial transcriptomics in cancer and neuroscience research, expansion of multiplex in situ hybridization techniques for multi-gene detection], restraints [high costs of in situ hybridization techniques, competition from alternative molecular diagnostic techniques (qPCR, NGS)], opportunities [advantages over other techniques such as immunohistochemistry (IHC), expansion in emerging markets, growing adoption of companion diagnostics (CDx) solutions], and challenges [technical complexities associated with in situ hybridization].
• Product Development/Innovation: Detailed insights on newly launched and approved products/services of the in situ hybridization market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the in situ hybridization market
• Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Bioview (Israel), NEOGENOMICS LABORATORIES (US), Qiagen (Netherlands), Bio-Techne. (US) and Biocare Medical (US), among others, in the in situ hybridization market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET SIZE ESTIMATION
  • 2.2.2 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW
• 4.2 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY OFFERING AND COUNTRY
• 4.3 IN SITU HYBRIDIZATION MARKET SHARE, BY END USER, 2024
• 4.4 IN SITU HYBRIDIZATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Technological innovations for advanced in situ hybridization capabilities
    • 5.2.1.2 Increasing adoption of in situ hybridization in precision medicines and laboratory-developed tests
    • 5.2.1.3 Rising demand for spatial transcriptomics in cancer and neuroscience research
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Competition from alternative molecular diagnostic techniques
    • 5.2.2.2 High cost of in situ hybridization techniques in research and clinical applications
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Advantages of in situ hybridization over competing technologies
    • 5.2.3.2 Rising adoption of companion diagnostic solutions
    • 5.2.3.3 High growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Technical complexities associated with in situ hybridization
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 ROLE IN ECOSYSTEM
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Fluorescence In Situ Hybridization (FISH)
    • 5.6.1.2 Chromogenic In Situ Hybridization (CISH)
    • 5.6.1.3 RNAscope
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Immunofluorescence (IF)
    • 5.6.2.2 Next-generation Sequencing (NGS)
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Immunohistochemistry (IHC)
• 5.7 PATENT ANALYSIS
  • 5.7.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN SITU HYBRIDIZATION PATENTS
  • 5.7.2 LIST OF KEY PATENTS
• 5.8 KEY CONFERENCES & EVENTS, 2025-2026
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 THREAT OF NEW ENTRANTS
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.11.2 AVERAGE SELLING PRICE TREND OF IN SITU HYBRIDIZATION CONSUMABLES, BY REGION, 2022-2024
• 5.12 INVESTMENT & FUNDING SCENARIO
• 5.13 REGULATORY LANDSCAPE
  • 5.13.1 REGULATORY FRAMEWORK
    • 5.13.1.1 North America
    • 5.13.1.2 Europe
    • 5.13.1.3 Asia Pacific
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.14 IMPACT OF AI/GEN AI ON IN SITU HYBRIDIZATION MARKET
  • 5.14.1 KEY USE CASES
  • 5.14.2 IMPACT OF AI ON IN SITU HYBRIDIZATION ECOSYSTEM
  • 5.14.3 FUTURE OF AI IN IN SITU HYBRIDIZATION ECOSYSTEM
• 5.15 IMPACT OF 2025 US TARIFF ON IN SITU HYBRIDIZATION MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 KEY TARIFF RATES
  • 5.15.3 PRICE IMPACT ANALYSIS
  • 5.15.4 IMPACT ON COUNTRY/REGION
    • 5.15.4.1 North America
      • 5.15.4.1.1 US
    • 5.15.4.2 Europe
    • 5.15.4.3 Asia Pacific
  • 5.15.5 IMPACT ON END-USE INDUSTRIES
    • 5.15.5.1 Hospitals & diagnostic laboratories
    • 5.15.5.2 Academic & research institutes
    • 5.15.5.3 Pharmaceutical & biotechnology companies
    • 5.15.5.4 Contract research organizations

6 IN SITU HYBRIDIZATION MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 KITS & REAGENTS
    • 6.2.1.1 Increasing demand for companion diagnostics and personalized medicines to support market growth
  • 6.2.2 PROBE & PROBE KITS
    • 6.2.2.1 Technological advancements in probe design and chemistry to propel market growth
  • 6.2.3 ACCESSORIES & OTHER CONSUMABLES
    • 6.2.3.1 Growing adoption of in situ hybridization in research and clinical diagnostics to aid market growth
• 6.3 INSTRUMENTS
  • 6.3.1 AUTOMATED IN SITU HYBRIDIZATION INSTRUMENTS
    • 6.3.1.1 Increased adoption of faster and more reliable automated systems to boost market growth
  • 6.3.2 MANUAL IN SITU HYBRIDIZATION INSTRUMENTS
    • 6.3.2.1 Persistent demand in emerging economies to maintain market growth
• 6.4 SOFTWARE
  • 6.4.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SOFTWARE TO SUPPORT GROWTH
• 6.5 SERVICES
  • 6.5.1 DATA INTERPRETATION SERVICES
    • 6.5.1.1 Increasing use of multiplex assays and spatial biology techniques to boost segment growth
  • 6.5.2 CUSTOM PROBE DESIGN SERVICES
    • 6.5.2.1 Rising demand for customized probes in research and drug development to favor market growth

7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
  • 7.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION (DNA-FISH)
    • 7.2.1.1 Extensive use in research and companion diagnostics to fuel segment growth
  • 7.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION (RNA-FISH)
    • 7.2.2.1 Rise in biomedical research activity to drive adoption of RNA-FISH technology
  • 7.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION (PNA-FISH)
    • 7.2.3.1 High sensitivity offered by PNA FISH to fuel precise and reliable detection at low probe concentrations
• 7.3 CHROMOGENIC IN SITU HYBRIDIZATION (CISH)
  • 7.3.1 COST-EFFECTIVENESS, PRESERVATION OF TISSUE MORPHOLOGY, AND EASE OF INTERPRETATION TO BOOST SEGMENT GROWTH

8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 CLINICAL DIAGNOSTIC APPLICATIONS
  • 8.2.1 CANCER DIAGNOSTICS
    • 8.2.1.1 Rising number of cancer cases and increasing focus on precision medicines to drive segment
  • 8.2.2 INFECTIOUS DISEASE DIAGNOSTICS
    • 8.2.2.1 Growing demand for high sensitivity and specificity diagnostic methods in resource-limited settings to spur market growth
  • 8.2.3 GENETIC DISEASE DIAGNOSTICS
    • 8.2.3.1 Rising adoption of prenatal and neonatal screening to propel segment growth
  • 8.2.4 OTHER CLINICAL DIAGNOSTIC APPLICATIONS
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 NEUROSCIENCE RESEARCH
    • 8.3.1.1 Growing focus on neurological research to increase R&D in neuroscience-based ISH technologies
  • 8.3.2 IMMUNOLOGY RESEARCH
    • 8.3.2.1 Rising prevalence of autoimmune diseases to support market growth
  • 8.3.3 OTHER RESEARCH APPLICATIONS
• 8.4 DRUG DISCOVERY & DEVELOPMENT
  • 8.4.1 RISING DEMAND FOR NUCLEIC ACID-BASED THERAPIES TO FAVOR MARKET GROWTH

9 IN SITU HYBRIDIZATION MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 9.2.1 RISING DEMAND FOR MOLECULAR TESTS AND INCREASING NEED FOR ACCURATE DISEASE DIAGNOSIS TO DRIVE MARKET
• 9.3 ACADEMIC & RESEARCH INSTITUTES
  • 9.3.1 INCREASING GOVERNMENT AND PRIVATE FUNDING FOR LIFE SCIENCE AND BIOMEDICAL RESEARCH TO FUEL MARKET GROWTH
• 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.4.1 INCREASING FOCUS ON DEVELOPING PRECISION TREATMENTS TO PROPEL MARKET GROWTH
• 9.5 CONTRACT RESEARCH ORGANIZATIONS
  • 9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES IN TISSUE DIAGNOSTICS TO SUPPORT MARKET GROWTH

10 IN SITU HYBRIDIZATION MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to dominate North American in situ hybridization market during study period
  • 10.2.3 CANADA
    • 10.2.3.1 Increasing cancer burden and expanding in situ hybridization applications in cancer research to propel market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Research advancements and corporate developments to fuel market growth
  • 10.3.3 UK
    • 10.3.3.1 High government healthcare investments in genomic research to support market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Rising government investment in pharmaceutical industry to propel market growth
  • 10.3.5 ITALY
    • 10.3.5.1 High R&D investments and advanced pharmaceutical industry to favor market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Growing focus on cancer biomarker development to aid market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Increased focus on precision medicine and local manufacturing of in situ hybridization technologies to spur market growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Stringent regulatory guidelines and large geriatric population to augment market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Rising awareness of cancer and genetic disorders to support market growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Robust government support and active genetic research to propel market growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Increased focus on genomic and diagnostic research to aid market adoption of in situ hybridization products
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Growing focus on precision diagnostics to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Increasing collaboration among key players to spur market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Kingdom of Saudi Arabia
      • 10.6.2.1.1 Expanding role of in situ hybridization products in research and clinical practice to boost market growth
    • 10.6.2.2 UAE
      • 10.6.2.2.1 Rising government support and incorporation of in situ hybridization technologies by hospitals to aid market growth
  • 10.6.3 REST OF GCC COUNTRIES
  • 10.6.4 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 GROWING DEMAND FOR GENOMICS INFRASTRUCTURE AND MOLECULAR DIAGNOSTICS TO PROPEL MARKET GROWTH
  • 10.7.2 MACROECONOMIC ANALYSIS FOR AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IN SITU HYBRIDIZATION MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region Footprint
    • 11.5.5.3 Offering footprint
    • 11.5.5.4 Technology footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of key startups/SMEs
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & APPROVALS
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Services/Solutions offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches & approvals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 DANAHER
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Services/Solutions offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 ABBOTT
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Services/Solutions offered
    • 12.1.3.3 MnM view
      • 12.1.3.3.1 Right to win
      • 12.1.3.3.2 Strategic choices
      • 12.1.3.3.3 Weaknesses & competitive threats
  • 12.1.4 THERMO FISHER SCIENTIFIC INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Services/Solutions offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Right to win
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses & competitive threats
  • 12.1.5 BIO-TECHNE
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Services/Solutions offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 AGILENT TECHNOLOGIES, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Services/Solutions offered
  • 12.1.7 QIAGEN
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Services/Solutions offered
  • 12.1.8 BIOCARE MEDICAL, LLC
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Services/Solutions offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 BIOVIEW
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Services/Solutions offered
  • 12.1.10 CREATIVE BIOARRAY
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Services/Solutions offered
  • 12.1.11 ABNOVA CORPORATION
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products/Services/Solutions offered
  • 12.1.12 ZYTOMICS
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products/Services/Solutions offered
  • 12.1.13 ENZO BIOCHEM INC.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products/Services/Solutions offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches
  • 12.1.14 CYTOTEST INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products/Services/Solutions offered
  • 12.1.15 GENEMED BIOTECHNOLOGIES, INC.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products/Services/Solutions offered
• 12.2 OTHER PLAYERS
  • 12.2.1 MOLECULAR INSTRUMENTS, INC.
  • 12.2.2 OXFORD GENE TECHNOLOGY IP LIMITED
  • 12.2.3 HISTO-LINE LABORATORIES
  • 12.2.4 METASYSTEMS
  • 12.2.5 BIOGENEX
  • 12.2.6 LGC BIOSEARCH TECHNOLOGIES
  • 12.2.7 BIODISCOVERY LLC
  • 12.2.8 KANEKA EUROGENTEC S.A.
  • 12.2.9 LIFE TECHNOLOGIES (INDIA) PVT. LTD.
  • 12.2.10 GENECOPOEIA, INC.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS